P
DNLI icon

Pitcairn’s Denali Therapeutics DNLI Stock Holding History

Pitcairn’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,423
Closed -$169K – 710
2025
Q1 		$169K Buy
12,423
+1,125
+10% +$21.6K 0.01% 691
2024
Q4 		$230K Buy
11,298
+39
+0.3% +$998 0.01% 651
2024
Q3 		$328K Buy
+11,259
New +$279K 0.02% 562
2023
Q3 		– Sell
-7,051
Closed -$208K – 657
2023
Q2 		$208K Buy
+7,051
New +$198K 0.02% 614

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pitcairn's DNLI Position: Q2 2025 in Review

Pitcairn sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 12,423 shares — an estimated $169K sold.

Pitcairn first reported a position in DNLI in Q2 2023 and held it in 4 quarters. The position peaked at $328K in Q3 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Pitcairn reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pitcairn sold 12,423 Denali Therapeutics shares in Q2 2025, an estimated $169K.
  • Pitcairn first reported a position in Denali Therapeutics in Q2 2023 and held it in 4 quarters.
  • Pitcairn's Denali Therapeutics position peaked at $328K in Q3 2024.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Pitcairn's 13F filing for Q2 2025, filed 14 Aug 2025.